X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2491) 2491
index medicus (2177) 2177
oncology (1789) 1789
male (1682) 1682
chemotherapy (1130) 1130
aged (1042) 1042
middle aged (1003) 1003
antineoplastic combined chemotherapy protocols - therapeutic use (902) 902
hematology (895) 895
treatment outcome (836) 836
mitoxantrone plus prednisone (804) 804
prostate cancer (800) 800
female (793) 793
cancer (711) 711
docetaxel (659) 659
adult (622) 622
care and treatment (615) 615
aged, 80 and over (592) 592
antineoplastic agents - therapeutic use (585) 585
survival (561) 561
elderly-patients (536) 536
prognosis (502) 502
therapy (479) 479
multiple myeloma (472) 472
prostatic neoplasms - drug therapy (464) 464
urology & nephrology (411) 411
rituximab (409) 409
stem-cell transplantation (406) 406
prednisone (392) 392
research (380) 380
non-hodgkins-lymphoma (379) 379
multiple myeloma - drug therapy (376) 376
trial (376) 376
disease-free survival (373) 373
double-blind (361) 361
bortezomib (357) 357
drug therapy (342) 342
prednisone - administration & dosage (340) 340
metastasis (337) 337
plus prednisone (324) 324
abiraterone acetate (316) 316
antineoplastic combined chemotherapy protocols - administration & dosage (316) 316
lymphoma, large b-cell, diffuse - drug therapy (315) 315
antineoplastic combined chemotherapy protocols - adverse effects (312) 312
survival analysis (311) 311
pharmacology & pharmacy (309) 309
chemotherapy plus rituximab (306) 306
randomized controlled-trial (303) 303
retrospective studies (287) 287
lymphomas (281) 281
prostatic neoplasms - pathology (270) 270
cyclophosphamide - administration & dosage (267) 267
phase-ii trial (260) 260
prostatic neoplasms, castration-resistant - drug therapy (257) 257
health aspects (256) 256
thalidomide (255) 255
analysis (248) 248
clinical trials (243) 243
doxorubicin - administration & dosage (242) 242
clinical trials as topic (239) 239
lenalidomide (235) 235
open-label (235) 235
survival rate (233) 233
neoplasm staging (232) 232
vincristine - administration & dosage (232) 232
cyclophosphamide (227) 227
prednisone - therapeutic use (225) 225
plus rituximab (224) 224
medicine & public health (216) 216
hematology, oncology and palliative medicine (215) 215
immunotherapy (215) 215
patient outcomes (215) 215
risk factors (213) 213
increased survival (212) 212
phase-ii (212) 212
b-cell lymphoma (211) 211
taxoids - therapeutic use (211) 211
patients (202) 202
disease progression (197) 197
men (196) 196
dexamethasone (195) 195
lenalidomide plus dexamethasone (194) 194
taxoids - administration & dosage (194) 194
transplantation (194) 194
animals (191) 191
cyclophosphamide - therapeutic use (187) 187
antineoplastic agents - administration & dosage (181) 181
review (181) 181
drug resistance, neoplasm (180) 180
neoplasm metastasis (180) 180
phase-iii trial (179) 179
thalidomide - analogs & derivatives (179) 179
antitumor-activity (178) 178
cancer therapies (178) 178
melphalan (177) 177
enzalutamide (175) 175
diffuse large b-cell lymphoma (173) 173
doxorubicin (173) 173
randomized-trial (173) 173
antineoplastic agents - adverse effects (172) 172
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3155) 3155
German (45) 45
French (44) 44
Spanish (17) 17
Polish (2) 2
Hungarian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 09/2006, Volume 107, Issue 5, pp. 1014 - 1022
BACKGROUND. in patients with advanced-stage follicullar lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach,... 
Chemotherapy | Randomized trial | Indolent lymphoma | First-line therapy | indolent lymphoma | first-line therapy | 1ST-LINE TREATMENT | INTERFERON-ALPHA-2B | randomized trial | PREDNIMUSTINE | PHASE-II | COMBINATION | chemotherapy | CHEMOTHERAPY PLUS RITUXIMAB | TRANSPLANTATION | SINGLE-AGENT | ONCOLOGY | MYELOABLATIVE RADIOCHEMOTHERAPY | NON-HODGKINS-LYMPHOMA | Doxorubicin - therapeutic use | Prednisolone - adverse effects | Chlorambucil - adverse effects | Lymphoma, Follicular - drug therapy | Chlorambucil - therapeutic use | Agranulocytosis - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Time Factors | Adult | Female | Prednisolone - therapeutic use | Mitoxantrone - adverse effects | Mitoxantrone - therapeutic use | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Survival Rate | Treatment Outcome | Thrombocytopenia - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Germany | Prednisone - therapeutic use | Chemotherapy, Combination | Lymphomas | Research | Drug therapy | Patient outcomes
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 934 - 941
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 355 - 362
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression‐free survival (PFS) and overall survival (OS) in multiple... 
SURVIVAL | THERAPY | METAANALYSIS | EFFICACY | INITIAL TREATMENT | PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | PHASE-3 | HEMATOLOGY | YOUNGER | TRANSPLANTATION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Pyrazines - administration & dosage | Drug Evaluation | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Male | Case-Control Studies | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Aged, 80 and over | Female | Retrospective Studies | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Bortezomib | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Thalidomide - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Nervous System Diseases - chemically induced | Aged | Multiple Myeloma - genetics | Evidence, Expert | Medical research | Corticosteroids | Analysis | Multiple myeloma | Medicine, Experimental | Prednisone | Consulting services | Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1532 - 1542
Journal Article
by Robak, Tadeusz and Jin, Jie and Pylypenko, Halyna and Verhoef, Gregor and Siritanaratkul, Noppadol and Drach, Johannes and Raderer, Markus and Mayer, Jiri and Pereira, Juliana and Tumyan, Gayane and Okamoto, Rumiko and Nakahara, Susumu and Hu, Peter and Appiani, Carlos and Nemat, Sepideh and Cavalli, Franco and Van Hoof, Achiel and Sheliga, Adriana and Teixeira, Adriana and Tomita, Akihiro and Rocafiguera, Albert Oriol and Suvorov, Alexander and Kuzmin, Alexy and Khojasteh, Ali and Mezlini, Amel and Golenkov, Anatoly and Bosly, Andre and Belch, Andrew and Van De Velde, Ann and Illes, Árpád and Mukhopadhyay, Ashis and Meddeb, Balkis and De Prijck, Bernard and Garichochea, Bernardo and Undar, Bulent and Gabarrón, Caballero and Cao, Carmen and Souza, Carmino and Farber, Charles and Won Suh, Cheol and Burcoveanu, Cristina Ileana and Cebotaru, Cristina Ligia and Truica, Cristina-Ligia and Maruyama, Dai and Belada, David and Ben Yehuda, Dina and Udovitsa, Dmitry and Dolores and Morra, Enrica and Späth-Schwalbe, Ernst and Gonzalez-Barca, Eva and Osmanov, Evgenii and Capote, Francisco Javier and Offner, Fritz and Cardenas, Galvez and Heß, Georg and Manikhas, Georgii and Babu, Govind and Rekhtman, Grigoriy and Rossi, Guiseppe and Marques, Herlander and Marques, Margarida and Bumbea, Horia and Wang, Zhao and Wang, Huaqing and Huang, Huiqiang and Choi, Ilseung and Bulavina, Irina and Lysenko, Irina and Avivi, Irit and Kryachok, Iryna and Zaucha, Jan Maciej and Novak, Jan and Díaz, Joaquín and Demeter, Judit and Alexeeva, Julia and Zhu, Jun and Vilchevskaya, Kateryna and Ishizawa, Kenichi and Mauricio, Kenny and Tobinai, Kensei and Ando, Kiyoshi and Abdulkadryrov, Kudrat and Shih, Lee-Yung and Kuzina, Lyudmila and Gumus, Mahmut and De Wit, Maike and Capra, Marcelo and Golubeva, Marina and Ojeda-Uribe, Mario and Kyselyova, Maryna and Taniwaki, Masafumi and Federico, Massimo and Crump, Michael and Baccarani, Michele and Ogura, Michinori and Egyed, Miklós and Udvardy, Miklos and Kurosawa, Mitsutoshi and Uike, Naokuni and ... and LYM-3002 investigators
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1449 - 1458
Journal Article
Blood, ISSN 0006-4971, 2016, Volume 127, Issue 9, pp. 1109 - 1116
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 4, pp. 448 - 455
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 417 - 425
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article